Ocugen (OCGN) Income towards Parent Company (2014 - 2026)
Ocugen (OCGN) posted Income towards Parent Company of -$35.9 million for Q1 2026, down 98.84% on a QoQ basis from -$18.0 million in Q4 2025, and down 131.98% year-over-year from $112.1 million in Q1 2025.
Ocugen (OCGN) Income towards Parent Company (2014 - 2026) Analysis & Trends
Ocugen's Income towards Parent Company history runs 13 years deep, the most recent figure standing at -$35.9 million for Q1 2026.
- Quarterly Income towards Parent Company fell 131.98% year-over-year to -$35.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$92.8 million (down 46.4% YoY) and the FY2025 annual result came in at -$198.0 million, down 14.43% from the prior year.
- Income towards Parent Company was -$35.9 million for Q1 2026 at Ocugen, down from -$18.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$13.0 million in Q3 2024 and bottomed at -$123.9 million in Q4 2023.
- A 5-year average of -$27.7 million and a median of -$21.0 million in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company sank 464.92% — and 2024, when it jumped 88.75%.
- Ocugen's Income towards Parent Company stood at -$21.9 million in 2022, then sank by 464.92% to -$123.9 million in 2023, then soared by 88.75% to -$13.9 million in 2024, then retreated by 29.36% to -$18.0 million in 2025, then plunged by 98.84% to -$35.9 million in 2026.
- Business Quant data shows OCGN's Income towards Parent Company at -$35.9 million in Q1 2026, -$18.0 million in Q4 2025, and -$18.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Ocugen | 399.60 Mn | 399.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.86 Mn |
| Dec 31, 2025 | -18.03 Mn |
| Sep 30, 2025 | -18.73 Mn |
| Jun 30, 2025 | -20.14 Mn |
| Mar 31, 2025 | -15.46 Mn |
| Dec 31, 2024 | -13.94 Mn |
| Sep 30, 2024 | -12.98 Mn |
| Jun 30, 2024 | -20.99 Mn |
| Mar 31, 2024 | -18.41 Mn |
| Dec 31, 2023 | -123.94 Mn |
| Sep 30, 2023 | -16.87 Mn |
| Jun 30, 2023 | -28.17 Mn |
| Mar 31, 2023 | -22.85 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -27.15 Mn |
| Mar 31, 2022 | -33.50 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |
| Jun 30, 2021 | -85.16 Mn |